Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights significant challenges: a GAAP net loss of $19.4 million, high cash burn, and competitive pressures. Despite initial revenue from product launches, financial sustainability is a concern. The Q&A reveals uncertainties in strategic partnerships and trial outcomes. These factors, coupled with increased costs and competitive risks, suggest a negative sentiment. Without strong guidance or partnerships, the stock is likely to face downward pressure.
Key Financial Performance
Total Revenue $86,000 in Q3 2025. This marks the initial revenues comprised of both nPulse capital and Vybrance disposable sales as the company initiated its limited market release.
Total GAAP Costs and Expenses $20.5 million in Q3 2025, an increase of $6.8 million compared to $13.7 million in the prior year period. The increase was primarily driven by expenses related to the expanding organization to support advancement of nsPFA device clinical trials and commercialization, along with noncash stock-based compensation.
Noncash Stock-Based Compensation $5.6 million in Q3 2025 compared to $3 million in the prior year period. This accounted for 38% of the year-over-year increase in costs and expenses.
Total Non-GAAP Costs and Expenses $14.6 million in Q3 2025, an increase of $4.2 million compared to $10.4 million in the prior year period.
GAAP Net Loss $19.4 million in Q3 2025 compared to $12.7 million in the prior year period. The increase reflects higher costs and expenses.
Non-GAAP Net Loss $13.5 million in Q3 2025 compared to $9.4 million in the prior year period.
Cash and Cash Equivalents $95.2 million as of September 30, 2025, compared to $79 million as of September 30, 2024. This represents a decrease of $11.1 million versus Q2 of 2025.
Cash Used in Operating Activities $13 million in Q3 2025 compared to $9 million in the prior year period and $12.8 million in Q2 of 2025. The increase was due to continued expense management and deliberate resource expansion.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
nPulse Vybrance percutaneous electrode system: New product and technology naming introduced. The proprietary nanosecond PFA platform is now called nPulse Technology, and the percutaneous electrode is named Vybrance. Over 200 patients treated in pilot programs and commercial procedures. Positive outcomes and growing utilization reported. Initial revenues recognized in Q3 2025.
nPulse cardiac surgery system: Received FDA investigational device exemption approval for atrial fibrillation treatment. First patient enrolled and treated in IDE study. European feasibility studies progressing with 44 patients treated. Promising initial data presented at the European Association for Cardiothoracic Surgery Meeting.
nPulse 360 Catheter: Designed for atrial fibrillation ablation. European feasibility study enrolled 150 patients. IDE submission progressing with FDA, study expected to commence in Q1 2026. New safety and efficacy data anticipated in Q1 2026.
Soft tissue ablation market: Vybrance system targets benign thyroid nodule treatment. Positive patient flow and insurance claims processing observed. Economic benefits highlighted compared to traditional thyroidectomy.
Cardiac ablation market: nPulse cardiac surgical system and 360 Catheter aim to address atrial fibrillation treatment. European feasibility studies and IDE submissions progressing. Potential for strategic partnerships in electrophysiology.
Commercialization efforts: Initial revenues of $86,000 recognized in Q3 2025. Focus on pilot programs, training, and market access. Expansion into new geographies planned after achieving desired utilization levels.
Regulatory progress: FDA IDE approval for nPulse cardiac surgery system. Ongoing IDE submission for nPulse 360 Catheter. European feasibility studies advancing for both devices.
Strategic focus: Advancing nPulse technology for soft tissue and cardiac ablation. Emphasis on clinical validation, market access, and patient outcomes. Exploring strategic partnerships in electrophysiology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company is engaged in regulatory processes for its devices, including FDA investigational device exemption (IDE) approvals and European feasibility studies. Delays or challenges in obtaining regulatory approvals could impact the timeline for product launches and market penetration.
Market adoption and utilization: The company is in the early stages of launching its nPulse Vybrance system and is focused on driving procedure counts and physician training. Slow adoption or lack of physician interest could hinder commercial success.
Reimbursement challenges: While there is a positive trend in insurance claims being processed, the company is still working to confirm market access for commercial reimbursement. Lack of payer support could limit patient access and procedural growth.
Financial sustainability: The company reported a GAAP net loss of $19.4 million for Q3 2025 and is using significant cash for operating activities. Sustained losses and high cash burn could impact long-term financial viability.
Competitive pressures: The company operates in a highly competitive market for medical devices, particularly in the areas of soft tissue ablation and atrial fibrillation treatment. Competitors with established market presence could pose challenges.
Clinical trial risks: The company is conducting multiple clinical studies, including the PRECISE-BTN study and IDE studies for cardiac devices. Delays, adverse outcomes, or failure to meet endpoints could impact regulatory approvals and market confidence.
Supply chain and operational risks: The company is expanding its organization and operations to support commercialization and clinical trials. Any disruptions in the supply chain or operational inefficiencies could delay product availability and increase costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Looking ahead, the company expects disposables and nPulse system sales to grow along with overall procedure acceptance. A large portion of procedures are currently being completed under the pilot program or as part of the PRECISE study, which are not included in revenue totals.
Commercial Expansion: The company plans to maintain consistent commercial headcount in Q4, focusing on expanding accounts in existing large metropolitan geographies. Once initial accounts achieve desired utilization levels, headcount will expand, and new geographies will be launched.
Clinical Studies and Regulatory Progress: The PRECISE-BTN study is progressing with more than 40% enrollment to date and is expected to complete enrollment in Q1 2026. Results will be reported in the next quarterly update. The IDE pivotal study for the nPulse surgical ablation clamp has been approved by the FDA, with the first patient enrolled and treated. The company plans to expand into additional sites by the end of the year and into Q1 2026. The IDE study for the nPulse 360 Catheter is expected to commence in Q1 2026 after resolving remaining open items with the FDA.
Market Trends and Adoption: The company is encouraged by positive trends in insurance claims being processed and paid, supporting the clinical value of procedures. The perceived safety benefits and economic arguments for the Vybrance procedure are expected to drive adoption and utilization. Long-term follow-up evaluations and additional data publications will play a critical role in scaling commercial efforts.
Strategic Partnerships: The company is exploring potential collaborations with established leaders in electrophysiology to accelerate growth and achieve significant market penetration. Updates on partnership progress will be shared as appropriate.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the pre-op lesion work set done in the NANOCLAMP trial? Is it one size fits all?
A:The lesion set varies based on the severity of the Afib burden. Surgeons have discretion in determining the lesion set, which can range from isolating veins to performing a full box maze.
Q:Is left atrial appendage closure part of the NANOCLAMP trial?
A:No, left atrial appendage closure is not part of the protocol. The trial focuses solely on the ablation procedure, and strokes will be adjudicated as per standard concomitant surgical protocols.
Q:In the NS 360 pivotal trial expected to begin in Q1, will Pulse fund this unilaterally or involve a strategic partner?
A:Pulse plans to fund the study unilaterally as the sponsor. However, they remain open to a partnership strategy, which could manifest during commercialization or even during the study. Any funding for the study is expected to come from Pulse's income statement.
Q:Can you share additional details on the performance criteria for the PRECISE-BTN study?
A:The study focuses on a composite endpoint, including volume reduction, total symptom burden, and quality of life based on an established thyroid patient scale. It aims to measure outcomes like speed of symptom elimination and reduction of compressive symptoms without compromising thyroid function.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on whether a strategic partner would fund the NS 360 trial, stating that it is speculative and to be determined. Additionally, while discussing the PRECISE-BTN study, the response lacked clarity on specific numerical performance benchmarks.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Annual
BTN study
Dr
IDE submission
Medical Center
Meeting
Nanosecond PFA
PRECISE BTN
ablation energy
ablation time
account geography
arm multicenter
candidate
community
effectiveness nPulse
electrode system
electrophysiology
initiation
market access
multicenter study
nPulse Catheter
nPulse clamp
nPulse electrode
nPulse system
naming
nanosecond
patient site
procedure patient
program PRECISE
safety effectiveness
safety efficacy
scale
study Europe
study patient
study procedure
surveillance
treatment fibrillation
utilization
PLSE Transcript
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral5-13
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call lacked substantial information on financial performance, strategic initiatives, or operational updates, leading to a neutral sentiment. The absence of clear guidance or significant announcements, combined with the acknowledgment of risks, does not indicate any strong market movement. Without explicit financial metrics or strategic developments, the stock price is unlikely to experience significant volatility.
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Unknown2-20
The earnings call reveals mixed signals: strong revenue growth and positive reception of nPulse, but increased non-GAAP costs and cash burn raise concerns. The strategic focus on partnerships and regulatory progress is promising, yet the lack of clear timelines for product releases and the decline in cash reserves temper optimism. The market may react cautiously, resulting in a neutral stock price movement.
PLSE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
